WashU Medicine researchers Ali Ellebedy, PhD, and Hanover Matz, PhD, have found that Moderna's mRNA flu vaccine that is currently under review by the FDA triggers an immune response against a wide array of flu strains, potentially offering stronger and longer-lasting protection.